301246SZSE
🚨 Material Event

Announcement of Resolutions from the Second Meeting of the Fifth Board of Directors

✨ AI Summary

On June 1, 2026, the Fifth Board of Directors of Hubei Hongyuan Pharmaceutical Technology Co., Ltd. convened its second meeting, where it approved the establishment of a special account for raised funds. The company will terminate the "Antiviral Raw Materials and Intermediates Project" and redirect 206.8 million yuan to the "Wuxue Hongyuan Lithium Battery New Energy Materials Integration Project." The decision was unanimously supported by the board members present.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· azure_openai

I. Meeting Information

The second meeting of the Fifth Board of Directors of Hubei Hongyuan Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "the Company") was held on June 1, 2026, in the company meeting room, both in person and via communication. The meeting notice and materials were delivered to all directors and senior management on May 25, 2026. The meeting was chaired by Mr. Yin Dan, the chairman of the board. There were 9 directors required to attend, and all 9 participated in the voting. Directors Mr. Yan Xiaohui, Mr. Chen Jiachun, Mr. Lu Shigang, and Mr. Zhou Kaitan attended via communication. The senior management of the company also attended the meeting. The convening of this board meeting complied with the relevant provisions of the Company Law and the Articles of Association, and the resolutions made were legal and valid.

Sign in to read the full translation

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.